Cyclin-Dependent Kinase Inhibitor p15
"Cyclin-Dependent Kinase Inhibitor p15" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An INK4 cyclin-dependent kinase inhibitor containing four ANKYRIN-LIKE REPEATS. INK4B is often inactivated by deletions, mutations, or hypermethylation in HEMATOLOGIC NEOPLASMS.
| Descriptor ID |
D050762
|
| MeSH Number(s) |
D12.644.360.225.100 D12.776.167.187.100 D12.776.476.225.100 D12.776.624.776.355.100
|
| Concept/Terms |
Cyclin-Dependent Kinase Inhibitor p15- Cyclin-Dependent Kinase Inhibitor p15
- Cyclin Dependent Kinase Inhibitor p15
- INK4B Protein
- CDKN2B Protein
- INK4b Cyclin-Dependent Kinase Inhibitor
- INK4b Cyclin Dependent Kinase Inhibitor
- p15INK4B Protein
- p15 CDK4 Inhibitor
- CDK4 Inhibitor, p15
- Cyclin-Dependent Kinase Inhibitor 2B
- Cyclin Dependent Kinase Inhibitor 2B
|
Below are MeSH descriptors whose meaning is more general than "Cyclin-Dependent Kinase Inhibitor p15".
Below are MeSH descriptors whose meaning is more specific than "Cyclin-Dependent Kinase Inhibitor p15".
This graph shows the total number of publications written about "Cyclin-Dependent Kinase Inhibitor p15" by people in this website by year, and whether "Cyclin-Dependent Kinase Inhibitor p15" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2012 | 0 | 3 | 3 |
| 2014 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclin-Dependent Kinase Inhibitor p15" by people in Profiles.
-
Methyltransferase Inhibition Enables Tgfß Driven Induction of CDKN2A and B in Cancer Cells. Mol Cell Biol. 2023; 43(3):115-129.
-
Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study. Genes Chromosomes Cancer. 2020 08; 59(8):484-494.
-
Linear and circular CDKN2B-AS1 expression is associated with Inflammatory Bowel Disease and participates in intestinal barrier formation. Life Sci. 2019 Aug 15; 231:116571.
-
Salivary Gland Secretory Carcinoma With High-Grade Transformation, CDKN2A/B Loss, Distant Metastasis, and Lack of Sustained Response to Crizotinib. Int J Surg Pathol. 2017 Oct; 25(7):613-618.
-
A variant at 9p21.3 functionally implicates CDKN2B in paediatric B-cell precursor acute lymphoblastic leukaemia aetiology. Nat Commun. 2016 Feb 12; 7:10635.
-
A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. Invest New Drugs. 2015 Apr; 33(2):371-9.
-
Germline rearrangements in families with strong family history of glioma and malignant melanoma, colon, and breast cancer. Neuro Oncol. 2014 Oct; 16(10):1333-40.
-
A genome-wide association study in the Japanese population confirms 9p21 and 14q23 as susceptibility loci for primary open angle glaucoma. Hum Mol Genet. 2012 Jun 15; 21(12):2836-42.
-
1000 Genomes-based imputation identifies novel and refined associations for the Wellcome Trust Case Control Consortium phase 1 Data. Eur J Hum Genet. 2012 Jul; 20(7):801-5.
-
Genome-wide association study for intracranial aneurysm in the Japanese population identifies three candidate susceptible loci and a functional genetic variant at EDNRA. Hum Mol Genet. 2012 May 01; 21(9):2102-10.